Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | getITD for FLT3-ITD-based MRD monitoring in AML

Lars Bullinger • 26 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia Midostaurin

Lars Bullinger, MD, Charité University of Medicine, Berlin, Germany, outlines the main aims and key findings in the evaluation of the analysis program, getITD, for FLT3-ITD-based minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Lars Bullinger

1:49
Bringing precision medicine and MRD into clinical strategies
Lars Bullinger • 15 Jun 2020
1:56
Minimal gene panel in AML
Lars Bullinger • 15 Jun 2020
2:09
EHA: AML immuno-oncology updates
Lars Bullinger • 15 Jun 2020
1:36
Innovations in MDS and AML treatment
Lars Bullinger • 15 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals